49 results on '"Gruver, Aaron M."'
Search Results
2. Pathologist-trained machine learning classifiers developed to quantitate celiac disease features differentiate endoscopic biopsies according to modified marsh score and dietary intervention response
3. Targeted Quantitative Mass Spectrometry Analysis of Protein Biomarkers From Previously Stained Single Formalin-Fixed Paraffin-Embedded Tissue Sections
4. Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
5. Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer
6. A novel immunohistochemical scoring system reveals associations of C-terminal MET, ectodomain shedding, and loss of E-cadherin with poor prognosis in oral squamous cell carcinoma
7. MET ectodomain shedding is associated with poor disease-free survival of patients diagnosed with oral squamous cell carcinoma
8. Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry
9. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
10. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
11. Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer
12. Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry
13. Automated Quantitative RNA in Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast Carcinoma
14. From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma
15. Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer.
16. A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone
17. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer
18. Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity
19. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma
20. Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET)
21. Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity.
22. Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer
23. Tu1352 FULLY AUTOMATED HISTOLOGICAL CLASSIFICATION OF CELL TYPES AND TISSUE REGIONS OF CELIAC DISEASE IS FEASIBLE AND CORRELATES WITH THE MARSH SCORE
24. Abstract 937: Quantitative assessment of CD200 and CD200R expression in lung cancer
25. Congenital Mesoblastic Nephroma
26. Quantitative assessment of CD200 and CD200R expression in lung cancer
27. MET ectodomain shedding is associated with poor disease-free survival of patients diagnosed with oral squamous cell carcinoma
28. The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C
29. Advanced Companion Diagnostics Facilities: Opportunity Favors the Prepared Laboratory
30. MET in gastric cancer with liver metastasis: The relationship betweenMETamplification and Met overexpression in primary stomach tumors and liver metastasis
31. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung
32. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification
33. A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib.
34. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
35. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFRMutation–Positive NSCLC Patients
36. Ultrasensitive RNA In Situ Hybridization for Detection of Restricted Clonal Expression of Low-Abundance Immunoglobulin Light Chain mRNA in B-Cell Lymphoproliferative Disorders
37. HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma
38. Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.
39. Modified Array-based Comparative Genomic Hybridization Detects Cryptic and Variant PML-RARA Rearrangements in Acute Promyelocytic Leukemia Lacking Classic Translocations
40. Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry
41. Fibrin-associated Large B-cell Lymphoma
42. Microdeletions at Apparently Balanced Translocation Breakpoints Are Biomarkers for Heightened Genomic Instability in Patients with Non-MLL Acute Myeloid Leukemia
43. Novel Ophthalmic Pathology in an Autopsy Case of Autosomal Dominant Retinal Vasculopathy With Cerebral Leukodystrophy
44. The interaction profile of homologous recombination repair proteins RAD51C, RAD51D and XRCC2 as determined by proteomic analysis
45. Functional characterization and identification of mouse Rad51d splice variants
46. Extensive Chromosomal Instability in Rad51d-Deficient Mouse Cells
47. Modified Array-based Comparative Genomic Hybridization Detects Cryptic and Variant PML-RARA Rearrangements in Acute Promyelocytic Leukemia Lacking Classic Translocations
48. Automated Quantitative RNA in SituHybridization for Resolution of Equivocal and Heterogeneous ERBB2(HER2) Status in Invasive Breast Carcinoma
49. Microdeletions at Apparently Balanced Translocation Breakpoints Are Biomarkers for Heightened Genomic Instability in Patients with Non-MLLAcute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.